TLR5 agonists are promising anticancer agents because of their safety, as well as their efficacy. Unlike many other TLRs, TLR5 signaling, while immunostimulatory, does not induce certain highly ...
today announced that Panacela Labs, Inc., a majority-owned subsidiary of CBLI, has entered into a contract valued at approximately 149 million rubles, or approximately $4.6 million, with the Ministry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results